Jon Hamilton

Sue Bell started taking Lekembe in 2020 as part of a clinical trial. In 2023, when Sue was 71, she described her memory this way.

Sue Bell started taking Lekembe in 2020 as part of a clinical trial. In 2023, when Sue was 71, she described her memory this way.

Ken is Sue's husband. We were chatting in their kitchen in St. Charles, Missouri. They were telling me how Sue's memory problems had begun about four years earlier. Did you know you were having memory problems? Could you tell? No. Well, now wait a minute.

Ken is Sue's husband. We were chatting in their kitchen in St. Charles, Missouri. They were telling me how Sue's memory problems had begun about four years earlier. Did you know you were having memory problems? Could you tell? No. Well, now wait a minute.

Ken is Sue's husband. We were chatting in their kitchen in St. Charles, Missouri. They were telling me how Sue's memory problems had begun about four years earlier. Did you know you were having memory problems? Could you tell? No. Well, now wait a minute.

Because you were doing some part-time substitute teaching. Sue would come home from work and tell Ken she was having trouble spelling words.

Because you were doing some part-time substitute teaching. Sue would come home from work and tell Ken she was having trouble spelling words.

Because you were doing some part-time substitute teaching. Sue would come home from work and tell Ken she was having trouble spelling words.

That's part of the problem.

That's part of the problem.

That's part of the problem.

That's how it really all started. Next came cognitive tests, brain scans, and a diagnosis, early-stage Alzheimer's. So in 2020, Sue volunteered for a study in St. Louis. Researchers there were studying an experimental drug. Sue knew it was unlikely to help her.

That's how it really all started. Next came cognitive tests, brain scans, and a diagnosis, early-stage Alzheimer's. So in 2020, Sue volunteered for a study in St. Louis. Researchers there were studying an experimental drug. Sue knew it was unlikely to help her.

That's how it really all started. Next came cognitive tests, brain scans, and a diagnosis, early-stage Alzheimer's. So in 2020, Sue volunteered for a study in St. Louis. Researchers there were studying an experimental drug. Sue knew it was unlikely to help her.

The drug was Lekembe, then known by its generic name, Lecanumab. It's designed to clear the brain of beta amyloid, which forms the sticky plaques that are a hallmark of Alzheimer's. Lekembe is one of two drugs on the market that can modify the disease process rather than just treat its symptoms. Sue and Ken began making twice-monthly trips to St.

The drug was Lekembe, then known by its generic name, Lecanumab. It's designed to clear the brain of beta amyloid, which forms the sticky plaques that are a hallmark of Alzheimer's. Lekembe is one of two drugs on the market that can modify the disease process rather than just treat its symptoms. Sue and Ken began making twice-monthly trips to St.

The drug was Lekembe, then known by its generic name, Lecanumab. It's designed to clear the brain of beta amyloid, which forms the sticky plaques that are a hallmark of Alzheimer's. Lekembe is one of two drugs on the market that can modify the disease process rather than just treat its symptoms. Sue and Ken began making twice-monthly trips to St.

Louis, where she got Lekembe by intravenous infusion.

Louis, where she got Lekembe by intravenous infusion.

Louis, where she got Lekembe by intravenous infusion.